Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium
Strata Oncology notes the data to be presented includes results for innovative, proprietary predictive biomarkers for response to anti-PD-1/PD-L1 immunotherapy and antibody-drug conjugates (ADCs) -- the Immunotherapy Response Score (IRS) and ADC Treatment Response Score (ADC TRS), respectively.